Krystal moves towards ‘full integration’ with gene therapy facility opening

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Adriano_cz)
(Image: Getty/Adriano_cz)

Related tags Krystal Biotech Gene therapy

Krystal opens cGMP facility for the clinical and commercial manufacture of its lead drug candidate, KB103, and plans to open its second in 2020.

After an opening ceremony for its Pennsylvania, US, facility, Krystal Biotech stated that it would build a second facility to become a fully-integrated gene therapy company.

The opening ceremony was preceded by a successful trial run of the manufacturing capabilities of the 4,500ft2​ site.

“Completing a successful trial run is another step towards our goal of becoming a fully integrated gene therapy company and continue to fulfil our commitment to fundamentally treating rare skin diseases in a painless, convenient and effective manner," ​said Suma Krishnan, founder and COO of Krystal.

While its second facility opening is in the works, Krystal’s newly opened current good manufacturing practice (cGMP), Pittsburgh site will handle the clinical and commercial manufacture of its lead product, KB103.

The drug candidate is a potential off-the-shelf, topical gene therapy for dystrophic epidermolysis bullosa, an incurable skin blistering condition caused by a lack of collagen protein in the skin.

Previously, CEO, Krish Krishnan, explained that KB103 would be delivered as a reverse thermal gel​, which is a liquid in frozen conditions and then solidifies at room temperature to be used topically – potentially allowing it to be administered by the patient themselves, at later stages of development.

According to the company, the next step towards full integration will be to create an additional, larger facility in Pittsburgh. The second site is expected to be completed by 2020 and will allow the biotech to meet future research, clinical and commercial demand for its pipeline of products.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Related suppliers

Follow us


View more